Selinexor: Preliminary Phase I/II data

Preliminary data from 10 evaluable patients with relapsed or refractory MM who previously received >=2 therapies including Revlimid

Read the full 184 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE